Research progress of alectinib in the treatment of ALK-positive non-small cell lung cancer / 中国肿瘤临床

ABSTRACT

Rizotinib is a first-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) and plays an important role in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC). However, as with other TKIs, resistance development can-not be avoided with crizotinib. This led to the development of second generation ALK-TKIs such as alectinib, ceritinib, and brigatinib. This article reviews the research progress on treatment of ALK-positive NSCLC with alectinib, which is one of the hotspots.